Integrated Investment Consultants’s BioMarin Pharmaceuticals BMRN Stock Holding History

Integrated Investment Consultants’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-962	Closed	-$78K	–	229
2018 Q1	$78K	Buy	+962	New	+$82.6K	0.03%	367
2017 Q3	$90K	Buy	962 +228	+31%	+$20.1K	0.04%	318
2017 Q2	$67K	Hold	734	–	–	0.03%	359
2017 Q1	$64K	Hold	734	–	–	0.03%	363
2016 Q4	$61K	Hold	734	–	–	0.03%	353
2016 Q3	$64K	Hold	734	–	–	0.03%	358
2016 Q2	$57K	Buy	734 +121	+20%	+$10.3K	0.03%	378
2016 Q1	$52K	Buy	+613	New	+$49.9K	0.03%	347

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Integrated Investment Consultants's BMRN Position: Q2 2018 in Review

Integrated Investment Consultants sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2018, closing a stake of 962 shares — an estimated $78K sold.

Integrated Investment Consultants first reported a position in BMRN in Q1 2016 and held it in 8 quarters. The position peaked at $90K in Q3 2017. 448 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

Integrated Investment Consultants reported no remaining BioMarin Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Integrated Investment Consultants sold 962 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $78K.
Integrated Investment Consultants first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 8 quarters.
Integrated Investment Consultants's BioMarin Pharmaceuticals position peaked at $90K in Q3 2017.
448 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on Integrated Investment Consultants's 13F filing for Q2 2018, filed 1 Aug 2018.